13 September 2018 - Subcutaneous formulation takes two to five minutes to administer, rather than up to 90 minutes with the standard intravenous formulation.

Roche Canada announced today that Health Canada has approved a subcutaneous (SC) formulation of Herceptin for the treatment of early and metastatic stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, an aggressive form of the disease.

The approval of Herceptin SC is based on longer term results from the Phase III HannaH study, which showed that the subcutaneous formulation demonstrated comparable efficacy to Herceptin administered intravenously in women with HER2-positive early breast cancer.

Read Roche press release